

## Time is Beta Cells: Teplizumab and Delaying Type 1 Diabetes

Mariam Diaby, PharmD | PGY1 Pharmacy Resident

Wellstar Cobb Medical Center

Wellstar Health System is Accredited by the Accreditation Council for Pharmacy Education as a Provider of Continuing Pharmacy Education.

There is no fee for this program.

This program has been approved for 1 contact hours (0.1 CEU).

This program is an **Application**-based CPE activity.

UAN: 0483-0000-26-008-L01-P

UAN: 0483-0000-26-008-L01-T

**Target Audience:** This activity is intended for pharmacists and pharmacy technicians.

**Date:** June 11, 2026 **Times:** 7:30 am – 8:30 am and 3:15 pm – 4:15 pm | **Cobb Auditorium**

**Location:** Wellstar Cobb Medical Center and Microsoft Teams

**Learning Objectives:** At the conclusion of this activity, participants will be able to:

### Pharmacists

- Describe the pathophysiology and staging of Type 1 diabetes, including the role of autoimmune  $\beta$ -cell destruction.
- Recognize the mechanism of action and clinical effects of teplizumab in delaying disease progression.
- Identify patients at risk for progression to Stage 3 Type 1 diabetes and appropriate candidates for teplizumab therapy.
- Apply evidence-based strategies for the use, monitoring, and management of teplizumab in clinical practice.

### Technicians

- Describe the purpose and basic mechanism of teplizumab in delaying Type 1 diabetes.
- Recognize common adverse effects and the importance of monitoring during therapy.
- Explain the basic administration process and infusion considerations for teplizumab.

Visit <https://wellstar.learningexpressce.com/> to login or sign-up

Participants who attend the entire activity, complete and pass the post-test (>70%), and complete the activity evaluation will receive CE credit. Credit will be uploaded electronically and available in CPE Monitor after completion of required elements.